MatsukiyoCocokara & Co. (MSMKF)
ValueMarkers Composite Index
61% above intrinsic value ($0)
MatsukiyoCocokara & Co. (MSMKF) — VMCI valuation read
MatsukiyoCocokara & Co. sits at VMCI 72/100, with the Healthcare sector median at 50. That 22-point spread is the first thing to note on MSMKF: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.
Form 4 disclosures on MSMKF are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.
**Investor frame.** The Value read on MSMKF: MSMKF trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 3.1x is the binding constraint on the bear case, anchoring the bear scenario on a measurable balance-sheet metric.
MSMKF rose 2.4% over the trailing 7 days, with a +7.1% read on a 30-day basis.
MatsukiyoCocokara & Co. operates a chain of drug stores and pharmacies in Japan. As of June 30, 2020, it operated through a network of 1,726 stores in 47 prefectures in Japan. MatsukiyoCocokara & Co. was founded in 1932 and is based in Matsudo, Japan.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.